Jump to content
  • Black Friday Sale

    20% off all courses, seminars, webcasts, elearning, publications and certification. Use code BF22.

    More Info
  • RQA Membership - Just £30 from 1st October

    From 1st Oct, membership for the remainder of 2022 will only cost £30

    Click now to join
  • Join our face to face courses this November

    Our residential courses are back - see what's available now

    View Courses

Who are RQA

The Research Quality Association (RQA) is a professional membership body dedicated to informing and advancing its members. We provide status and visibility for individuals engaged in the quality of research concerning pharmaceuticals, agrochemicals, chemicals and medical devices. Since our inception in 1977, the Association has increased and evolved to reflect regulatory changes, the growing impact of regulatory inspection and the ever-changing structure and needs of industry. RQA's purpose is to drive quality and integrity in scientific research.  

Read more+

Our vision

To inspire quality, integrity and compliance in scientific research.

Our mission

To provide knowledge and learning in the scientific research community by building expertise through training, communication, engagement and collaboration.

Newsletter

Sign up to the latest news and events.

Latest News

View all news

ICH - The ICH E19 Introductory Training Presentation is now available on the ICH website

The ICH E19 Introductory Training Presentation is now available on the ICH website

Read more+

MHRA - Process for approving Manufacturing Authorisations or API Registrations in relation to unlicensed Cannabis-Based Products for Medicinal Use

Several companies have contacted the MHRA regarding cannabis-based products for medicinal use. This blog provides information on what authorisations are required in order to MHRA Manufacturing Licence Application manufacture within this sector of the pharmaceutical industry.

Read more+

WHO - WHO releases first data on global vaccine market since COVID-19

This is the first report to capture the implications of COVID-19 for vaccine markets.

Read more+
Virtual Event Platform